COMMENTWIRE: Breo approved in COPD, but others are breathing down its neck
This article was originally published in Scrip
GlaxoSmithKline can push ahead with a new franchise in COPD (and possibly asthma) but it really only has months to go before the competition starts to get out there on the market.
You may also be interested in...
The recent Respiratory Effectiveness Group (REG) Summit provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. Dr Natasha Spiller was there to look at a new battle ground for top-selling mainstay respiratory therapies, Spiriva, Symbicort and Advair.
It has been an eventful week in chronic obstructive pulmonary disease (COPD). New safety data emerged for Spiriva Respimat (tiotropium; Boehringer Ingelheim) and encouraging analyses from Novartis’ LABA/LAMA Ultibro Breezhaler from the European Respiratory Society (ERS) Annual Congress: while Anoro (umeclidinium/vilanterol), GlaxoSmithKline’s fixed-dose long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) inhaler, has been recommended for approval by the US FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC).
The expected entry of Ultibro Breezhaler into the COPD market following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on 25 July will considerably advance Novartis's position within the market.